Robert M. Gow

Robert M. Gow

Auto-generated profile, based on publicly available information

Robert M. Gow

Department of Pediatrics, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Heart Rhythm
Verified
Journal Article
Closed access
CPCaileigh M. Pilmer
Caileigh M. Pilmer
JKJoel A. Kirsh
Joel A. Kirsh
DHDoris Hildebrandt
Doris Hildebrandt
AKAndrew D. Krahn
Andrew D. Krahn
RGRobert M. Gow
Robert M. Gow

1 April 2015 in International Journal of Cardiology
Verified
Journal Article
Closed access
YXYanwei Xi
Yanwei Xi
CHChristina Honeywell
Christina Honeywell
Dapeng ZhangDapeng Zhang
Dapeng Zhang
JSJeremy Schwartzentruber
Jeremy Schwartzentruber
CBChandree L. Beaulieu
Chandree L. Beaulieu
RGRobert M. Gow
Robert M. Gow

15 August 2010 in Channels
Verified
Journal Article
Closed access
PDF file
DJDawei Jiang
Dawei Jiang
PJPeter P. Jones
Peter P. Jones
DDDarryl Davis
Darryl Davis
RGRobert Gow
Robert Gow
MGMartin Green
Martin Green
MGMichael H. Gollob
Michael H. Gollob
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an arrhythmogenic disease that manifests as syncope or sudden death during high adrenergic tone in the absence of structural heart defects. It is primarily caused by mutations in the cardiac ryanodine receptor (RyR2). The mechanism by which these mutations cause arrhythmia remains controversial, with discrepant findings related to the role of the RyR2 binding protein FKBP12.6. The purpose of this study was to characterize a novel RyR2 mutation identified in a kindred with clinically diagnosed CPVT. Single-strand conformational polymorphism analysis and direct DNA sequencing were used to screen the RyR2 gene for mutations. Site-directed mutagenesis was employed to introduce the mutation into the mouse RyR2 cDNA. The impact of the mutation on the interaction between RyR2 and a 12.6 kDa FK506 binding protein (FKBP12.6) was determined by immunoprecipitation and immunoblotting and its effect on RyR2 function was characterized by single cell Ca2+ imaging and [3H]ryanodine binding. A novel CPVT mutation, E189D, was identified. The E189D mutation does not alter the affinity of the channel for FKBP12.6, but it increases the propensity for store-overload-induced Ca2+ release (SOICR). Furthermore, the E189D mutation enhances the basal channel activity of RyR2 and its sensitivity to activation by caffeine. The E189D RyR2 mutation is causative for CPVT and functionally increases the propensity for SOICR without altering the affinity for FKBP12.6. These observations strengthen the notion that enhanced SOICR, but not altered FKBP12.6 binding, is a common mechanism by which RyR2 mutations cause arrhythmias.

1 February 2002 in Cardiac Electrophysiology Review
Verified
Journal Article
Closed access
PDF file
RGRobert M. Gow
Robert M. Gow

4 September 2014 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
ASAdrienne Stevens
Adrienne Stevens
CHCandyce Hamel
Candyce Hamel
KSKavita Singh
Kavita Singh
MAMohammed T Ansari
Mohammed T Ansari
EMEsther Myers
Esther Myers
MTMark Tremblay
Mark Tremblay
Cardiovascular disease and type 2 diabetes are examples of chronic diseases that impose significant morbidity and mortality in the general population worldwide. Most chronic diseases are associated with underlying preventable risk factors, such as elevated blood pressure, high blood glucose or glucose intolerance, high lipid levels, physical inactivity, excessive sedentary behaviours, and overweight/obesity. The occurrence of intermediate outcomes during childhood increases the risk of disease in adulthood. Sugar-sweetened beverages are known to be significant sources of additional caloric intake, and given recent attention to their contribution in the development of chronic diseases, a systematic review is warranted. We will assess whether the consumption of sugar-sweetened beverages in children is associated with adverse health outcomes and what the potential moderating factors are. Of interest are studies addressing sugar-sweetened beverage consumption, taking a broad perspective. Both direct consumption studies as well as those evaluating interventions that influence consumption (e.g. school policy, educational) will be relevant. Non-specific or multi-faceted behavioural, educational, or policy interventions may also be included subject to the level of evidence that exists for the other interventions/exposures. Comparisons of interest and endpoints of interest are pre-specified. We will include randomized controlled trials, controlled clinical trials, interrupted time series studies, controlled before-after studies, prospective and retrospective comparative cohort studies, case–control studies, and nested case–control designs. The MEDLINE®, Embase, The Cochrane Library, CINAHL, ERIC, and PsycINFO® databases and grey literature sources will be searched. The processes for selecting studies, abstracting data, and resolving conflicts are described. We will assess risk of bias using design-specific tools. To determine sets of confounding variables that should be adjusted for, we have developed causal directed acyclic graphs and will use those to inform our risk of bias assessments. Meta-analysis will be conducted where appropriate; parameters for exploring statistical heterogeneity and effect modifiers are pre-specified. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach will be used to determine the quality of evidence for outcomes. PROSPERO CRD42014009641 .

30 April 2008 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
RGRobert M. Gow
Robert M. Gow
NBNicholas J. Barrowman
Nicholas J. Barrowman
LLLillian Lai
Lillian Lai
DMDavid Moher
David Moher